ArticleJournal of gastrointestinal oncology2026
Hedyotis diffusa Willd suppresses hepatocellular carcinoma tumor-stromal interactions by inactivating cancer-associated hepatic stellate cells.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hedyotis diffusa Willd (HDW) has the effects of clearing the heat, removing the toxins, restoring the circulation, eliminating the stasis and promoting the process of diuresis. Variety formulations of HDW various formulas involving HDW show remarkable clinical effects and have become second-lines anticancer drugs in China. However, its underlying mechanism against hepatocellular carcinoma (HCC) remains unclear. The objective of this study is to investigate the functional effect of HDW in the treatment of HCC, and to clarify the mechanism of HDW in suppression of tumor-stromal interaction. Methods: Therapeutic effects of HDW on HCC cells and cancer-associated hepatic stellate cells (HSCs) were investigated in vitro and in vivo. Potential targets of HDW were predicted and signaling pathway analyses were conducted using network pharmacology. The HDW-target gene set (HDW-TGS) was systematically screened to investigate the mechanisms by which HDW influences tumor-stromal interactions and to identify target genes with significant clinical value. Results: HDW induced HCC cells apoptosis via reactive oxygen species (ROS) induction. HDW-TGS significantly correlated to prognosis in The Cancer Genome Atlas (TCGA) HCC samples. HDW suppressed activated-HSC migration and invasion by regulating expression of fibrosis markers α-SMA and p-ERK1/2. In an HCC cell and HSC splenic co-transplanted xenograft mouse model, HDW suppressed liver tumor formation by downregulating fibrosis, indicating that HDW inhibited tumor-stromal interactions in vivo. Finally, we revealed a potential downstream target of HDW in HCC. We proposed that HDW might interrupt tumor-stromal interaction via ADH4. Conclusions: This study provides a new perspective for the treatment of HCC with HDW, demonstrating the feasibility of ADH4 as an HCC treatment target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.